Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane and gemcitabine in borderline unresectable pancreatic cancer
NCT02124369Phase 2Terminated
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Jul 2014
- Primary completion
- Jul 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel in pancreatic ductal adenocarcinoma (PDAC), sponsored by Cambridge Clinical Trials Unit. Started Jul 2014; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02124369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124369.